{"schema_version":"secwatch.filing_event.v1","accession":"0000105770-23-000004","form_type":"8-K","ticker":"WST","cik":"0000105770","company_name":"WEST PHARMACEUTICAL SERVICES INC","filed_at":"2023-02-16T23:59:59+00:00","discovered_at":"2026-05-14T18:03:43.689514+00:00","generated_at":"2026-06-19T08:38:23.885187+00:00","sec_items":["2.02","7.01","8.01","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"West Pharma Q4 revenue -3% to $708.7M, adj. EPS $1.77; FY23 guidance $7.25-$7.40, $1B buyback","bullets":["Q4 net sales $708.7M (-3.0% reported, +2.6% organic); reported EPS $1.36, adjusted EPS $1.77.","Full-year 2022 net sales $2.887B (+2.0% reported, +7.7% organic); reported EPS $7.73, adjusted EPS $8.58.","FY 2023 guidance: net sales $2.935-2.960B, adj. EPS $7.25-7.40; COVID sales ~$85M (vs $388M in 2022).","Board approved new $1.0B share repurchase program, no expiration; prior program expired Dec 31, 2022.","Operating cash flow $724.0M (+24%); free cash flow $439.4M (+32.9%); capex $284.6M."],"urls":{"canonical":"https://secwatch.observer/filing/0000105770-23-000004","json":"https://secwatch.observer/filing/0000105770-23-000004.json","markdown":"https://secwatch.observer/filing/0000105770-23-000004.md","text":"https://secwatch.observer/filing/0000105770-23-000004.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/105770/000010577023000004/0000105770-23-000004-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/105770/000010577023000004/wst-20230215.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-19T08:38:23.885187+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"0e11b253d22703b1afeeed56321028f4d5b3154d","claim":"WEST PHARMACEUTICAL SERVICES INC reported full-year 2023 results: revenue $2.935 billion to $2.960 billion, EPS $7.25 to $7.40. Guidance initiated.","evidence_excerpt":"The Company is introducing full-year 2023 financial guidance of net sales in a range of $2.935 billion to $2.960 billion and adjusted-diluted EPS in a range of $7.25 to $7.40.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/105770/000010577023000004/0000105770-23-000004-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"full-year 2023"},{"label":"Revenue","value":"$2.935 billion to $2.960 billion"},{"label":"EPS","value":"$7.25 to $7.40"},{"label":"Guidance","value":"initiated"},{"label":"Result","value":"guidance update"}],"fact_type":"earnings_release"},{"claim_id":"18e29004bd62023241357820d8cd00235ff84df9","claim":"WEST PHARMACEUTICAL SERVICES INC reported the fourth-quarter and full-year 2022 results: revenue $708.7 million. Guidance initiated.","evidence_excerpt":"West Pharmaceutical Services, Inc. (NYSE: WST) today announced its financial results for the fourth-quarter and full-year 2022 and introduced full-year 2023 financial guidance. Fourth-Quarter and Full-Year 2022 Summary (comparisons to prior-year period) • Fourth-quarter 2022 net sales of $708.7 million declined 3.0%; organic net sales growth was 2.6%","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/105770/000010577023000004/0000105770-23-000004-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the fourth-quarter and full-year 2022"},{"label":"Revenue","value":"$708.7 million"},{"label":"Guidance","value":"initiated"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}